ECSP10010642A - Derivados de arilpirazinona como estimulantes de la secrecion de insulina, metodos para obtenerlos y su uso para el tratamiento de diabetes - Google Patents

Derivados de arilpirazinona como estimulantes de la secrecion de insulina, metodos para obtenerlos y su uso para el tratamiento de diabetes

Info

Publication number
ECSP10010642A
ECSP10010642A EC2010010642A ECSP10010642A ECSP10010642A EC SP10010642 A ECSP10010642 A EC SP10010642A EC 2010010642 A EC2010010642 A EC 2010010642A EC SP10010642 A ECSP10010642 A EC SP10010642A EC SP10010642 A ECSP10010642 A EC SP10010642A
Authority
EC
Ecuador
Prior art keywords
derivatives
diabetes
treatment
stimulants
insulin secretion
Prior art date
Application number
EC2010010642A
Other languages
English (en)
Inventor
Gerard Botton
Christine Charon
Eric Valeur
Micheline Kergoat
Samer Elbawab
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of ECSP10010642A publication Critical patent/ECSP10010642A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/18—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invencion se refiere a derivados de arilpirazinona de la formula (I), en donde R1, R2, R3 y A son tal como se define en la reivindicacion 1, como estimulantes de la secrecion de insulina. La invencion tambien se refiere a la preparacion y al uso de estos derivados de pirazinona para la prevencion y/o el tratamiento de diabetes y patologias asociadas. (I)
EC2010010642A 2008-04-29 2010-11-26 Derivados de arilpirazinona como estimulantes de la secrecion de insulina, metodos para obtenerlos y su uso para el tratamiento de diabetes ECSP10010642A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08008165 2008-04-29

Publications (1)

Publication Number Publication Date
ECSP10010642A true ECSP10010642A (es) 2010-12-30

Family

ID=40589704

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010010642A ECSP10010642A (es) 2008-04-29 2010-11-26 Derivados de arilpirazinona como estimulantes de la secrecion de insulina, metodos para obtenerlos y su uso para el tratamiento de diabetes

Country Status (25)

Country Link
US (2) US8815859B2 (es)
EP (1) EP2268624B1 (es)
JP (1) JP5498482B2 (es)
KR (1) KR101687419B1 (es)
CN (1) CN102015661B (es)
AR (1) AR071518A1 (es)
AU (1) AU2009242720B2 (es)
BR (1) BRPI0910833A2 (es)
CA (1) CA2722813C (es)
CO (1) CO6310997A2 (es)
CY (1) CY1114531T1 (es)
DK (1) DK2268624T3 (es)
EA (1) EA022345B1 (es)
EC (1) ECSP10010642A (es)
ES (1) ES2433210T3 (es)
HR (1) HRP20130992T1 (es)
IL (1) IL208959A (es)
MX (1) MX2010011792A (es)
NZ (1) NZ589555A (es)
PL (1) PL2268624T3 (es)
PT (1) PT2268624E (es)
SI (1) SI2268624T1 (es)
UA (1) UA103191C2 (es)
WO (1) WO2009132739A1 (es)
ZA (1) ZA201008505B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011002846A (es) * 2008-09-26 2011-04-07 Hoffmann La Roche Derivados de pirina o pirazina para tratar el virus de la hepatitis c.
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013066838A1 (en) * 2011-10-31 2013-05-10 Glaxosmithkline Llc Compounds and methods
CN104628661A (zh) * 2015-02-05 2015-05-20 北京理工大学 一类喹喔啉酮衍生物作为醛糖还原酶抑制剂的结构、制备方法及用途
CN114907323B (zh) * 2022-05-31 2023-08-15 内蒙古民族大学 喹喔啉酮类化合物及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62198671A (ja) 1986-02-25 1987-09-02 Toyo Jozo Co Ltd １−置換アルキル１，２−ジヒドロ−２−ピラジノン誘導体
MXPA03010324A (es) 2001-05-14 2004-02-17 Bristol Myers Squibb Pharma Co PIRAZINONAS, PIRIDINAS Y PIRIMIDINAS SUBSTITUIDAS COMO LIGANDOS DEL FACTOR DE LIBERACIoN DE CORTICOTROPINA.
ATE353693T1 (de) 2002-07-19 2007-03-15 Biovitrum Ab Neue piperazinyl-pyrazinon-derivate zur behandlung von 5-ht2a rezeptor-bedingten erkrankungen
FR2857867B1 (fr) * 2003-07-25 2005-10-14 Oreal Utilisation en coloration capillaire de derives de ninhydrine portant un groupe heteroalkyle
CN1938031A (zh) 2004-03-29 2007-03-28 默克公司 作为钠通道阻滞剂的联芳取代的吡嗪酮类
WO2006050506A1 (en) * 2004-11-03 2006-05-11 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
TW200640881A (en) * 2005-02-15 2006-12-01 Du Pont Fungicidal pyrazine derivatives
JP5193878B2 (ja) * 2005-12-21 2013-05-08 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｍｃｈ−１が媒介する疾患における使用のための新規な置換ピラジノン誘導体
CA2652859A1 (en) * 2006-06-21 2007-12-27 E.I. Du Pont De Nemours And Company Pyrazinones as cellular proliferation inhibitors

Also Published As

Publication number Publication date
CY1114531T1 (el) 2016-10-05
EP2268624B1 (en) 2013-07-31
NZ589555A (en) 2012-08-31
CN102015661A (zh) 2011-04-13
SI2268624T1 (sl) 2013-12-31
CA2722813C (en) 2017-03-21
WO2009132739A1 (en) 2009-11-05
US20110046159A1 (en) 2011-02-24
HRP20130992T1 (hr) 2013-11-22
US20140329837A1 (en) 2014-11-06
US9233937B2 (en) 2016-01-12
JP5498482B2 (ja) 2014-05-21
KR20100135313A (ko) 2010-12-24
KR101687419B1 (ko) 2016-12-19
EA201001688A1 (ru) 2011-06-30
JP2011518847A (ja) 2011-06-30
ZA201008505B (en) 2012-01-25
AU2009242720B2 (en) 2014-03-27
EP2268624A1 (en) 2011-01-05
AU2009242720A1 (en) 2009-11-05
BRPI0910833A2 (pt) 2015-08-11
US8815859B2 (en) 2014-08-26
CN102015661B (zh) 2014-05-14
AR071518A1 (es) 2010-06-23
IL208959A (en) 2015-09-24
EA022345B1 (ru) 2015-12-30
ES2433210T3 (es) 2013-12-09
PT2268624E (pt) 2013-11-07
CA2722813A1 (en) 2009-11-05
UA103191C2 (ru) 2013-09-25
CO6310997A2 (es) 2011-08-22
MX2010011792A (es) 2010-11-25
PL2268624T3 (pl) 2014-01-31
IL208959A0 (en) 2011-01-31
DK2268624T3 (da) 2013-11-04

Similar Documents

Publication Publication Date Title
CO6300954A2 (es) Derivados de tienopiridinonas como activadores de proteina quinasa activados por ampk
CL2011001082A1 (es) Compuestos derivados de amino-tetrahidropiranos sustituidos con heterociclos, composicion farmaceutica; y uso en el tratamiento de una afeccion seleccionada de resistencia a la insulina, hiperglicemia y diabetes de tipo 2.
MX2010009576A (es) Derivados de quinoxalinona como estimulantes de la secrecion de insulina, metodos para obtenerlos y su uso en el tratamiento de la diabetes.
UY29636A1 (es) 2,4-diamino-pirimidinas como inhibidores de aurora
MA32811B1 (fr) Nouveaux composés
MA33939B1 (fr) 5-alcynyl-pyrimidines
ECSP10010654A (es) Derivados de tienopiridonas como activadores de proteína quinasa activados por amp (ampk)
UY32799A (es) Derivados de oxazina y su uso en el tratamiento de trastornos neurológicos
ECSP12012065A (es) Derivados de pirazina y su uso en el tratamiento de trastornos neurológicos
CO6311079A2 (es) Derivados de aminodihidrotiazina como inhibidores de la enzima bace para el tratamiento de la enfermedad de alzheimer
EA201001639A1 (ru) Композиции и способы их получения и применения
MY149648A (en) Carboxylalkylene-phenyl)-phenyl-oxalamides, method for the production thereof, and use of same as a medicament
TN2012000010A1 (en) Long acting insulin composition
BR112012018345A2 (pt) "compostos de heteroarila, bem como composições e usos dos mesmos"
UY32648A (es) Nuevos derivados de pirimidina y su uso en el tratamiento de enfermedades
UY32543A (es) Análogos de isoxazol-3(2h)-ona como agentes terapéuticos
IN2012DN01531A (es)
ECSP11010760A (es) Derivados de quinoxalindiona
MX2010002419A (es) (ciclopropilfenil) feniloxamidas, metodo para su produccion y uso como un medicamento.
MA32505B1 (fr) 5-alcynyl-pyrimidines
JO2682B1 (en) Derivatives of alkynil-8.1-naphthayridone, preparations thereof and therapeutic use thereof
EA201201623A1 (ru) Лечение диабета 2 типа
ECSP11010816A (es) Nuevos Compuestos
CU20100111A7 (es) 4-(4-ciano-2-tioaril)dihidropirimidinonas y su uso para el tratamiento y prevención de enfermedades pulmonares y cardiovasculares
MX2010009575A (es) Derivados de pirazinonas como estimulantes de la secrecion de insulina, metodos para obtenerlos y su uso en el tratamiento de la diabetes.